Skip to content
Brand AI

Lib Therapeutics

Request correction

Corporate brand

UnclaimedRead 2× by AI crawlers

A privately held, commercial-stage biopharmaceutical company developing lerodalcibep, a novel third-generation PCSK9 inhibitor for LDL-C reduction.

Last updated September 1, 2026

AI crawler reads

2requests

1companies
  • Anthropic2
Profile
2
Controversies
0
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company dedicated to bringing novel, highly effective, and safe therapies to help people with cardiovascular disease and familial hypercholesterolemia achieve their LDL-C goals. Its lead product candidate, lerodalcibep, is a novel, third-generation PCSK9 inhibitor designed as a convenient once-monthly subcutaneous treatment.

History

LIB Therapeutics was founded in 2015 by an experienced team. The company is privately held and commercial-stage, focused on developing lerodalcibep, a novel third-generation PCSK9 inhibitor for LDL-C reduction.

Products and positioning

  • Lerodalcibep

    A novel, third-generation PCSK9 inhibitor developed as a convenient once-monthly subcutaneous treatment to reduce LDL-C.

Sources2 sources

  1. 1LIB Therapeuticslibtherapeutics.com
  2. 2LIB Therapeutics LLC (United States)wikidata.org

Cite this profile: Cite the canonical profile. /brand-wiki/lib-therapeutics · Editorial policy · How profiles are compiled